Characterization of Aerosols of Human Recombinant Deoxyribonuclease I (rhDNase) Generated by Jet Nebulizers

Recombinant human deoxyribonuclease I (rhDNase) is a new therapeutic agent developed to improve clearance of purulent sputum from the human airways. It is delivered by inhalation. Four jet nebulizers, T Up-Draft II (Hudson), Customized Respirgard II (Marquest), Acorn II (Marquest), and Airlife Misty (Baxter), were evaluated in vitro for their ability to deliver aerosols of rhDNase. The aerosols were generated from 2.5-mL aqueous solutions of rhDNase, at concentrations of either 1 or 4 mg/mL. In all experiments, the Pulmo-Aide Compressor (De Vilbiss) was used to supply the air to the nebulizers. Between 20 and 28% of the rhDNase dose initially placed in the nebulizers was delivered to the mouthpiece in the respirable range (1-6 µm). Evaluation of the rhDNase following nebulization in all four devices indicated that there was no loss in enzymatic activity and no increase in aggregation. Circular dichroism spectrophotometry indicated there was no change in either the secondary or the tertiary structure in rhDNase following nebulization. These results show that all four nebulizers are essentially equivalent in their ability to deliver respirable doses of rhDNase in an intact, fully active form. Changing the concentration of the solution in the nebulizer from 4 to 1 mg/mL rhDNase leads to a proportional reduction in the respirable dose delivered to the mouthpiece.     

Pharmacokinetics of peptide T in patients with Acquired Immunodeficiency Syndrome (AIDS)

1. The pharmacokinetics of Dalal-peptide T-NH2 (peptide T) was determined during phase I clinical trials in patients with acquired immunodeficiecy disease (AIDS) and AIDS related complex (ARC). Drug levels were determined by specific RIA, and in some cases with HPLC analysis, after intraveneous (i.v.) or intranasal (i.n.), via metered sprayer, administration.

2. The plasma kinetics appeared to be bi-phasic with a first compartment half-life of 30 to 60 minutes and a second plasma clearence rate of 4 to 6 hours, observed for both routes of administration. Peptide T, in one individual was confirmed to be present at 6 hrs in plasma, determined after HPLC isolation followed by specific RIA.

3. Bioavailabilty, determined for a 2 mg test dose in six individuals was 9.3 ± 6.9 nmol/L. Peak plasma levels of 41 ± 30 nmol/L after 10 mg i.n., 2.8 ± 5.9 nmol/L after 2mg i.n., and 0.13 ± 0.07 nmol/L after 0.4 mg i.n. were observed. In two individuals tested, peptide T was detected in CSF at levels 20% of the corresponding plasma level 90 and 145 minutes post i.v. administration. Peptide T was not detected in urine. I.N. administration was well tolerated for times up to 21 months.     

产程中应用杜冷丁对产程及新生儿的影响

目的　观察杜冷丁对产程及新生儿的影响。方法　将 16 0例初产妇随机分为观察组和对照组 ,各 80例 ,观察组在宫口开大 1.2cm时杜冷丁 10 0mg肌肉注射 ,对照组未用药。结果　第一产程用药组与对照组相比明显缩短 ,有显著差异 (P <0 .0 5 ) ,第二、三产程无差异 (P >0 .0 5 ) ,对新生儿影响、产后 2小时内出血量及新生儿体重两组无差异 (P >0 .0 5 )。结论　产程中应用杜冷丁可减轻产妇疼痛 ,缩短第一产程 ,不增加新生儿窒息 ,值得推广应用     

善宁治疗顽固性大咯血疗效观察

目的 评价善宁对顽固性大咯血的疗效。方法 将55例传统药物抢救无效或有禁忌的大咯血分为治疗组（善宁）与对照组（立止血组），观察24—72h的止血效果。结果 治疗组总有效率为92％，对照组为70％，两组比较有显著差异p〈0．05（x^2=4．125）。结论 善宁治疗大咯血疗效显著，使用安全，不良反应少，值得临床推广应用。     

蝮蛇抗栓酶-3治疗糖尿病并发症94例

应用腹蛇抗栓酶-3治疗94例糖尿病患者并发的脑血栓形成、高脂血症、动脉硬化、神经病变和心绞痛取得较好的疗效。脑血栓形成急性期采用冲击疗法,瘫痪肢体功能恢复迅速、合并神经病变者,治疗后症状消失、神经功能改善。TG、TC、β-脂蛋白水平和TC/HDL比值均降低(P<0.01),HDL水平上升(P<0.01),对比治疗前后血6-Keto-PGF_(1α)、TXB_2和纤维结合素FN的水平改善,具有统计学意义(P<0.01)。     

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease.

Manipulation of gamma-aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1-minute hand-tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed.     

黄芪注射液治疗心力衰竭46例临床观察

目的　探讨黄芪注射液对心力衰竭 (HF)的治疗效果。方法　选择 92例住院HF患者随机分为治疗组和对照组 ,对照组给予常规治疗 ,治疗组在常规治疗的基础上给予黄芪注射液 30ml加 5 %葡萄糖液 2 5 0ml,静滴 ,每日一次 ,共 2周。疗程结束后 ,观察心功能改善情况。结果　治疗组有效率 93.4 8% ,对照组有效率 71.74 % ,两组对比 ,差异显著 (P <0 .0 1)。结论　黄芪注射液对HF的治疗效果佳 ,副作用少 ,值得推广。     

8-硝基白杨素的合成及其抗肿瘤作用

目的　探讨 8-硝基白杨素的抗肿瘤活性。方法　荷Lewis肺癌雄性小鼠 5 0只 ,随机分为5组 (NS对照组 ,环磷酰胺组 ,低、中、高剂量 8-硝基白杨素组 ) ,每组 1 0只 ,均采用腹腔注射给药。末次给药 2 4h后 ,颈椎脱位处死小鼠 ,观察各组瘤重减轻情况及转移结节数。结果　低、中、高剂量 8-硝基白杨素均能明显抑制肿瘤的生长和肿瘤转移结节的数 (阳性药对照组和各处理组与对照组相比 ,P均<0 .0 1 ) ,高剂量 ( 5 0mg kg) 8-硝基白杨素与 1 0 0mg kg的环磷酰胺的抗肿瘤作用相当 (P >0 .0 5 )。结论　 8-硝基白杨素作为一种新黄酮衍生物 ,具有良好的抗肿瘤作用。     

丙种球蛋白治疗危重早产儿临床分析

目的 为评估IVIG治疗危重早产儿的临床疗效。方法 将危重早产儿116例采取随机分为治疗组和对照组，对照组给常规综合治疗，治疗组在常规综合治疗措施上，加用IVIG静脉滴注，比较治疗组与对照组患儿病情平稳率及死亡率。结果 IVIG治疗危重早产儿病情平稳率第5天达75．8％第10天达93．3％，而对照组分别为50％和70．4％；病死率治疗组为6．4％，对照组为11．1％，均优于常规对照组。结论 危重早产儿用IVIG治疗疗效较满意，值得推广。     

HD-91-2型肝病治疗仪治疗脂肪肝24例临床观察

[目的]探讨脂肪肝有效治疗方法。[方法]采用HD-91-2型肝病治疗仪、中药穴位透入、推按运经治疗脂肪肝24例。[结果]总有效率为91.67%。[结论]HD-91-2型肝病治疗仪作为一非药物治疗脂肪肝又一途径,是值得临床推广。